Selvita

Selvita R&D per Employee

The R&D Spending per Employee of Selvita (SLV.WA) as of Oct 23, 2026 is 115,782.90 PLN. In the previous year, R&D Spending per Employee was 49,879.64 PLN — a change of 132.12% (higher).

R&D per Employee

115,782.90PLN

YoY

132.12%

Last updated:

R&D Spending per Employee of Selvita is 2025 115,782.90 PLN. R&D Spending per Employee of Selvita was 2024 49,879.64 PLN. It decreases by 132.12% higher compared to the previous year.

The Selvita R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
5,224.97 PLN
Jan 1, 2021
6,758.16 PLN
Jan 1, 2022
8,326.21 PLN
Jan 1, 2023
55,203.60 PLN
Jan 1, 2024
49,879.64 PLN
Jan 1, 2025
115,782.90 PLN
The Selvita R&D per Employee history
YEARR&D per EmployeeYoY
115,782.90PLN+132.12%
49,879.64PLN-9.64%
55,203.60PLN+563.01%
8,326.21PLN+23.20%
6,758.16PLN+29.34%
5,224.97PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

R&D Spending per Employee of Selvita is 115,782.90 PLN in 2025.

R&D Spending per Employee of Selvita changed from 49,879.64 PLN to 115,782.90 PLN, representing a 132.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Selvita since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Selvita historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Selvita

All Key Metrics — Selvita